Drug Profile
Research programme: protease inhibitors - Virobay
Alternative Names: VBY-106; VBY-285; VBY-825Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Virobay
- Class Small molecules
- Mechanism of Action Cathepsin B inhibitors; Cathepsin inhibitors; Cathepsin S inhibitors; Hepatitis C protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Autoimmune disorders; Bone cancer; Neuropathic pain
- Discontinued Cancer pain; Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Autoimmune-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Bone-cancer in USA
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Neuropathic-pain in USA (PO)